Cirrhosis - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 67 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Cirrhosis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Cirrhosis - Pipeline Review, H2 2014', provides an overview of the Cirrhosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cirrhosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cirrhosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cirrhosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cirrhosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cirrhosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cirrhosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cirrhosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cirrhosis Overview 6
Therapeutics Development 7
Pipeline Products for Cirrhosis - Overview 7
Pipeline Products for Cirrhosis - Comparative Analysis 8
Cirrhosis - Therapeutics under Development by Companies 9
Cirrhosis - Therapeutics under Investigation by Universities/Institutes 10
Cirrhosis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Cirrhosis - Products under Development by Companies 13
Cirrhosis - Products under Investigation by Universities/Institutes 14
Cirrhosis - Companies Involved in Therapeutics Development 15
Gilead Sciences, Inc. 15
Novartis AG 16
Ocera Therapeutics, Inc. 17
Hyperion Therapeutics, Inc. 18
Intercept Pharmaceuticals, Inc. 19
PharmaIN Corporation 20
Alfact Innovation 21
Cirrhosis - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
ornithine phenylacetate - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
glycerol phenylbutyrate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
obeticholic acid - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
simtuzumab - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Stem Cell Therapy for Gastrointestinal, CNS and Endocrine and Metabolic Disorders - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
erismodegib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ALF-5755 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
PGC Based Natriuretic Peptides - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Cirrhosis - Recent Pipeline Updates 48
Cirrhosis - Dormant Projects 60
Cirrhosis - Product Development Milestones 61
Featured News & Press Releases 61
Nov 01, 2013: Salix Pharmaceuticals Outlines Data Presentations at American Association for the Study of Liver Diseases Annual Meeting 61
Sep 19, 2013: Les Laboratoires Servier Receives CHMP Positive Opinion For Valdoxan 61
Sep 17, 2013: Vasopressin V2 Receptor Antagonist Samsca 7.5mg Tablets Granted Additional Indication in Japan for the Treatment of Fluid Retention in Patients with Hepatic Cirrhosis 62
May 02, 2013: Hyperion Therapeutics Receives Orphan Drug Exclusivity From FDA 62
Nov 12, 2012: Hyperion Therapeutics Announces Presentation Of Results From Phase II HALT-HE Study At 63rd Annual Meeting Of AASLD 62
Nov 09, 2012: Salix Pharma Announces Presentation Of Xifaxan Data At 63rd Annual Meeting Of AASLD 63
Nov 05, 2011: Janssen Presents New Data On INCIVO At American Association For Society Of Liver Disease Annual Meeting 64
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67

List of Tables
Number of Products under Development for Cirrhosis, H2 2014 7
Number of Products under Development for Cirrhosis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Cirrhosis - Pipeline by Gilead Sciences, Inc., H2 2014 15
Cirrhosis - Pipeline by Novartis AG, H2 2014 16
Cirrhosis - Pipeline by Ocera Therapeutics, Inc., H2 2014 17
Cirrhosis - Pipeline by Hyperion Therapeutics, Inc., H2 2014 18
Cirrhosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2014 19
Cirrhosis - Pipeline by PharmaIN Corporation, H2 2014 20
Cirrhosis - Pipeline by Alfact Innovation, H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 30
Cirrhosis Therapeutics - Recent Pipeline Updates, H2 2014 48
Cirrhosis - Dormant Projects, H2 2014 60